Page last updated: 2024-11-06

ocaperidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ocaperidone is an atypical antipsychotic drug that is being investigated for the treatment of schizophrenia. It acts as a dopamine D2 receptor antagonist and a serotonin 5-HT2A receptor antagonist. Research suggests that ocaperidone may have a more favorable side effect profile than other atypical antipsychotics, particularly with regard to metabolic effects. Ocaperidone is studied because it has the potential to be a more effective and safer treatment for schizophrenia than currently available medications. Its mechanism of action, potential benefits, and safety profile are all areas of active research.'

ocaperidone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71351
CHEMBL ID2104619
CHEBI ID188525
SCHEMBL ID122321
MeSH IDM0195845

Synonyms (52)

Synonym
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[2,1-b]pyrimidin-4-one
gtpl46
PDSP1_000799
129029-23-8
D02675
ocaperidone (usan)
PDSP2_000787
ocaperidone
L001106
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4h-pyrido(1,2-a)pyrimidin-4-one
3-[2-[4-(6-luoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
CHEBI:188525
nsc_71351
cas_129029-23-8
bdbm84734
CHEMBL2104619
r-79598
ocaperidona [inn-spanish]
ocaperidona
ocaperidonum [inn-latin]
ocaperidonum
r 79598
4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2,9-dimethyl-
26hus7139v ,
unii-26hus7139v
ocaperidone [usan:inn:ban]
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-2,9-dimethyl-4h-pyrido[1,2-a]pyrimidin-4-one
ocaperidone [usan]
ocaperidone [inn]
SCHEMBL122321
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4h-pyrido[1,2-a]-pyrimidin-4-one
ZZQNEJILGNNOEP-UHFFFAOYSA-N
DTXSID10156042
AKOS030530792
AS-74911
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2,9-dimethyl-4h-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-pyrido[1,2-a]pyrimidin-4-one
HY-101094
CS-0020804
3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2,9-dimethyl-4h-pyrido[1,2-a]pyrimidin-4-one
DB06229
mfcd00866668
r79598
O0498
3-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4h-pyrido[1,2-a]pyrimidin-4-one
Q15633971
BCP32651
r 79598; r-79598; r79598; r 79,598; r-79,598; r79,598
4h-pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-
C72178
A920198

Research Excerpts

Overview

Ocaperidone is concluded to be a highly potent and efficacious dopamine-D2 antagonist with concomitant, equivalent serotonin 5-HT2 antagonism.

ExcerptReferenceRelevance
"Ocaperidone is concluded to be a highly potent and efficacious dopamine-D2 antagonist with concomitant, equivalent serotonin 5-HT2 antagonism."( Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Awouters, FH; Janssen, PA; Meert, TF; Megens, AA; Niemegeers, CJ; Schellekens, KH, 1992
)
1.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridopyrimidineAny organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A1997The Journal of biological chemistry, Mar-21, Volume: 272, Issue:12
5-HT1A receptor activates Na+/H+ exchange in CHO-K1 cells through Gialpha2 and Gialpha3.
AID624231Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D1996Molecular pharmacology, Dec, Volume: 50, Issue:6
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1997The Journal of biological chemistry, Mar-21, Volume: 272, Issue:12
5-HT1A receptor activates Na+/H+ exchange in CHO-K1 cells through Gialpha2 and Gialpha3.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1998British journal of pharmacology, Apr, Volume: 123, Issue:8
Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1996Molecular pharmacology, Dec, Volume: 50, Issue:6
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (66.67)18.2507
2000's2 (22.22)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.68 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]